ClinicalTrials.gg

BridgeBio clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 48 studies whose lead sponsor is BridgeBio or one of 13 companies grouped under it. 11 are recruiting or about to start. Per ClinicalTrials.gov, last updated Nov 12, 2026.

Our grouping of 13 registry names, not the registry’s. See them and correct one ↓

Compare BridgeBio with Alnylam Pharmaceuticals and AbbVie →

Pipeline: 6 programs

Each counted once: 6 with a study BridgeBio leads registered in the last two years.

  • Phase 2
  • Phase 3
  • Phase 4 (approved, new studies)

The 3 phase-3 programs — sign in to see them, free: with every program, filter by condition or phase and sort by first study or primary completion.

“Registry” is the highest phase of BridgeBio’s own registered studies; BridgeBio’s own pipeline document is not read yet. “Primary completion” is the earliest date still ahead among its live studies when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced. Programs are read from ClinicalTrials.gov, joined across names by rules and decisions each recorded with its evidence.

What it is testing

The drugs BridgeBio’s studies test, most open studies first — 6 drugs with a page of their own. Each count opens the studies in search.

Open now Not open: under way, finished or stopped

Coming up

2 of BridgeBio’s studies under way reach primary completion within a year, all of them phase 3. The dates are the sponsor’s own estimates, which often move.

Phase 3 Other phases

  1. N’26
  2. D
  3. 1J’27
  4. F
  5. M
  6. A
  7. M
  8. J
  9. J
  10. A
  11. 1S
  12. O
  13. N

Add all 2 to your calendar (.ics) → With an account.

All 48 at a glance

Where each study is in its life, its phase and its countries. Each count opens them in search.

  • Open now1123%Recruiting 7 · Enrolling by invitation 3 · Not yet recruiting 1
  • Under way, not recruiting715%
  • Completed1940%
  • Stopped early1123%Terminated 9 · Withdrawn 2

Phase

  • Phase 218
  • Phase 316
  • Phase 112
  • Phase 41

Where

  • United States44
  • United Kingdom24
  • Australia20
  • Canada18
  • Spain18
  • Italy15

Over the years

  1. 12
  2. 13
  3. 14
  4. 15
  5. 16
  6. 17
  7. 18
  8. 19
  9. 20
  10. 1021
  11. 22
  12. 23
  13. 24
  14. 25
  15. 626

By the year each study started. 2026 so far in the lighter column.

Registry sponsor names on this page

Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.

Tell us about a missing company
No account needed. Please leave out personal details.

Each name exactly as ClinicalTrials.gov lists it, and how it relates to BridgeBio.

  • Eidos Therapeutics, a BridgeBio company
    Acquired — became part of BridgeBio, Apr 2016 · source ↗
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    11 studies →
  • QED Therapeutics, a BridgeBio company
    Subsidiary
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    8 studies →
  • Origin Biosciences
    Subsidiary
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    5 studies →
  • Calcilytix Therapeutics, Inc., a BridgeBio company
    Subsidiary
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    5 studies →
  • ML Bio Solutions, Inc.
    Acquired — became part of BridgeBio, Jul 2019 · source ↗
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    4 studies →
  • TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
    Divested — left BridgeBio, Apr 30, 2024 · 2 more first submitted after it left, not counted · source ↗
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    1 study →
  • QED Therapeutics, Inc.
    Subsidiary
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    3 studies →
  • Navire Pharma Inc., a BridgeBio company
    Subsidiary
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    3 studies →
  • Phoenix Tissue Repair, Inc.
    Subsidiary
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    3 studies →
  • Adrenas Therapeutics Inc
    Subsidiary
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    2 studies →
  • Venthera, Inc., a BridgeBio company
    Subsidiary
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    1 study →
  • CoA Therapeutics, Inc., a BridgeBio company
    Subsidiary
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    1 study →
  • Cantero Therapeutics, a BridgeBio company
    Subsidiary
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    1 study →

Focus areas

Conditions BridgeBio leads ten or more studies in, by study count. A broader condition is left out when almost all its studies are already in a narrower one listed here.

Studies

Recruiting first, then most recently updated. Showing 48 of 48.